粘液屏障削弱了基于醇的聚醇对α-葡萄糖酶的抑制活性
Yi Wang1, Suqing Lan1,2, Laiming Zhang1
1College of Biosystems Engineering and Food Science, National-Local Joint Engineering Laboratory of Intelligent Food Technology and Equipment, Zhejiang Key Laboratory for Agro-Food Processing, Zhejiang Engineering Laboratory of Food Technology and Equipment, Zhejiang University, Hangzhou, PR China.
Molecular nutrition & food research
|March 20, 2025
概括
小肠粘液屏障显著降低了多的体内α-葡萄糖酶抑制活性. 克服这一障碍是开发有效的多基治疗食后高血糖症的关键.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 胃肠病学 胃肠病学
背景情况:
- 聚醇在体外表现出强大的α-葡萄糖酶抑制,超过了阿卡尔的抑制.
- 然而,它们在管理食后高血糖症的体内疗效有限,这是一个持续的挑战,阻碍了临床应用.
研究的目的:
- 研究小肠粘液层在调节特定多的体内α-葡萄糖酶抑制活性方面的作用.
- 阐明聚-粘液相互作用背后的机制及其对α-葡萄糖酶抑制的影响.
主要方法:
- 利用多光谱学,风学,溶剂提取和分子对接来分析多-氨酸相互作用.
- 在体内评估了这些相互作用对多醇透和与α-葡萄糖酶结合的影响.
主要成果:
- 鉴定了小肠粘液作为一种阻碍物,减少了epigallocatechin gallate,prodelphinidin B digallate (proDB DG) 和中国海叶 proanthocyanidins 的体内α-葡萄糖酶抑制活性.
- 在基于 pyrogallol 的多和乳之间,已证明强烈的相互作用 (结合,疏水性,静电性),阻碍了多进入α-glucosidase.
- 观察到,聚醇诱导的粘素聚合增强了粘液屏障,延迟了碳水化合物的消化和吸收.
结论:
- 粘液屏障显著损害了基于醇的多的体内α-葡萄糖酶抑制作用.
- 克服粘液屏障的策略代表了一种有前途的治疗方法,用于改善以多为基础的饮食后高血糖的调节.
- 这项研究为从聚醇中开发新的临床α-葡萄糖酶抑制剂铺平了道路.
相关概念视频
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
139
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
139
Dipeptidyl Peptidase 4 Inhibitors
148
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
148
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
329
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
329
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
352
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
352
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
324
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
324
Enzyme Inhibition
77.7K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
77.7K


